EF

Ellen Feigal

Prescient Therapeutics Limited | Non-Executive Director
Dr Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. Dr Feigal was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine, a research foundation working to accelerate development of new disease modifying treatments and cures for patients with chronic diseases; Executive Medical Director, Global Development at US biotech company Amgen Inc (NASDAQ: AMGN); Vice President of Clinical Sciences at the Translational Genomics Research Institute, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute.

Company and Role

Company
Title
Tenure
Since
PTX
Prescient Therapeutics Limited
  • Non-Executive Director
3yrs, 2mthMay 2023

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
PTX
Prescient Therapeutics Limited
18/11/25N/AN/A2,628,787N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
PTX
Prescient Therapeutics Limited
18/11/25
Issued
1,213,787$0.048$58,261Issue of options